Precision Genomic Markers for Immuno-Oncology
We are advancing the development of precision genomic biomarkers to predict responses to immune checkpoint blockade (ICB) in tumors characterized by low tumor mutation burden (TMB) and/or low PD-L1 expression. One such genomic marker, intragenic rearrangement burden (IRB), has shown promise in predicting ICB efficacy in TMB-low infiltrated tumor entities. Most recently, we reported a groundbreaking metric, tumor-associated antigen burden for evaluating tumor antigenicity in PD-L1-negative patients (in two issues of Cancer Immunology Res., 2024).
